Calcium hydroxyapatite ceramic implants in bone tumour surgery. A long-term follow-up study

Area of Science:

• Orthopedic Surgery
• Biomaterials Science
• Oncology

Background:

• Benign bone tumors require effective treatment and bone reconstruction.
• Calcium hydroxyapatite ceramic (CHA) is a synthetic bone graft substitute with potential applications in orthopedic surgery.

Purpose of the Study:

• To evaluate the efficacy and safety of curettage and calcium hydroxyapatite ceramic (CHA) implantation for treating benign bone tumors.
• To assess long-term outcomes and complications associated with CHA use in this patient cohort.

Main Methods:

• Retrospective review of 51 patients with benign bone tumors treated with curettage and CHA implantation.
• Mean follow-up period of 11.4 years (range: 10-15.5 years).
• Radiographic assessment of CHA incorporation and clinical evaluation for complications.

Main Results:

• CHA demonstrated good incorporation into host bone in all patients.
• Low complication rates: 2 post-operative fractures, 3 local recurrences, 3 cases of limited joint movement, and 1 case of mild osteoarthritis.
• No allergic or neoplastic complications were observed.
• CHA absorption was greater in males and younger patients, but complete absorption did not occur in any case.

Conclusions:

• Calcium hydroxyapatite ceramic (CHA) is a useful and safe bone substitute for benign bone tumor treatment.
• Long-term follow-up indicates good integration and acceptable complication profile.
• CHA offers a viable option for bone reconstruction following tumor removal.